ID   BIONi010-C-NKX2.5-T2A-Nluc-44.37
AC   CVCL_C0VT
SY   #44.37
DR   Wikidata; Q114310752
RX   PubMed=33660062;
CC   Population: African.
CC   Biotechnology: Part of the PluriLum assay which is used for predicting developmental toxicity which relies on the formation of embryoid bodies (EBs) and the differentiation of these into cardiomyocytes (PubMed=33660062).
CC   Characteristics: Using CRISPR/Cas9 a T2A-Nluc construct was inserted at the C-terminus of both alleles of NKX2-5 (PubMed=33660062).
CC   Genetic integration: Method=CRISPR/Cas9; Gene=NanoLuc (Note=19 kDa ATP-independent bright luminescent protein derived from O.gracilirostris).
CC   Derived from site: In situ; Skin, dermis; UBERON=UBERON_0002067.
CC   Cell type: Fibroblast of skin; CL=CL_0002620.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1E68 ! BIONi010-C
SX   Male
AG   18Y
CA   Induced pluripotent stem cell
DT   Created: 22-09-22; Last updated: 10-09-24; Version: 5
//
RX   PubMed=33660062; DOI=10.1007/s00204-021-03018-y; PMCID=PMC8113199;
RA   Lauschke K., Treschow A.F., Rasmussen M.A., Davidsen N., Holst B.,
RA   Emneus J., Taxvig C., Vinggaard A.M.;
RT   "Creating a human-induced pluripotent stem cell-based NKX2.5 reporter
RT   gene assay for developmental toxicity testing.";
RL   Arch. Toxicol. 95:1659-1670(2021).
//